


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound represented by formula (I):




wherein R₁s are the same or different ~~1-32~~ groups, each of them is selected from the group consisting of C1-3 alkyl ~~and C1-3 alkoxy~~; or when R₁s are two adjacent groups, the two R₁s taken together may form a saturated ~~or unsaturated~~ 5- or 6- membered cyclic group which may have 1 or 2 hetero atoms selected from the group consisting of sulfur, nitrogen and oxygen:

X is oxygen or sulfur:


R₂ is selected from the group consisting of phenyl, benzyl, pyridyl, pyridylmethyl, pyrimidinyl, cyclohexyl, methylpiperazinyl, indanyl, 1,3-benzodioxolyl and naphthyl, all of which may optionally be substituted; provided that when R₂ is phenyl, the 3- and 4- positions of the phenyl moiety are not substituted by alkoxy groups at the same time:

----- represents a single bond or double bond: and


L is




wherein n is an integer of 1-8;



wherein R_3 is selected from the group consisting of hydrogen, linear or branched C1-8 alkyl, C1-3 alkyl substituted by at least one fluorine atoms, cyclopentyl, cyclohexyl, cycloheptyl, cyclohexylmethyl, benzyl, 2-pyridyl and 2-pyrimidinyl groups, n' is an integer of 1-3;




wherein W is oxygen or sulfur atom, A is selected from the group consisting of linear or branched C1-5 alkyl, 2-dimethylaminoethylamino, 2-thiazolylamino, 4-methylhomopiperazinyl, 4-piperidinopiperidino, dimethylaminoanilino, pyridylamino, piperidino, 4-ethoxycarbonyl piperidino, 4-carboxypiperidino and a group represented by formula (J)




wherein R_3 is as defined above,

n'' is an integer of 0-3;




wherein E is selected from the group consisting of hydrogen, linear or branched C1-6 alkyl or alkenyl, C1-3 alkyl substituted by at least one fluorine atoms, 2-methoxyethyl, 2-methylthioethyl, 2-dimethylaminoethyl, phenyl, pyridyl, benzyl, pyridylmethyl, cyclopentyl, cyclohexyl, tetrahydro-2H-pyranyl, cyclohexylmethyl, 1-methyl-4-piperidyl indanyl, 1,3-benzodioxolyl and 1H-indolyl, wherein phenyl and pyridyl may optionally be substituted by


the group consisting of halogen, methyl, methoxy, isopropyl and allyl, ~~provided that when R₁ is 7-methoxy and R₂ is phenyl, E is not alkyl, and n' is an interger of 0-3;~~




wherein T is oxygen, sulfur or NH, G is selected from the group consisting of hydrogen, linear or branched C1-5 alkyl, C1-3 alkyl substituted by at least one fluorine atoms, 2-methoxyethyl and alkylcarbonyl, n' is an integer of 1-3;




wherein R₃ is as defined above;




wherein R₃ is as defined above;



wherein E is as defined above;



wherein R₃ is as defined above; or




wherein E is as defined above

or a salt thereof.

2. (Currently Amended) The compound of Claim 1, wherein R_1 s are two groups and selected from the group consisting of methyl[,], and ethyl ~~and methoxy~~.

3. (Original) The compound of Claim 2, wherein R_1 is 5,6-dimethyl.

4. (Currently Amended) The compound of Claim 1, which is represented by formula (I-1)



wherein M represents together with the isoindoline structure a saturated ~~or unsaturated~~ 5- or 6-membered cyclic group which may optionally have 1 or 2 hetero atoms selected from the group consisting of sulfur, nitrogen and oxygen;

X , R_2 and L are as defined in Claim 1

or a salt thereof.

5. (Original) The compound of Claim 4, wherein M is selected from the group consisting of


$-\text{CH}_2\text{CH}_2\text{CH}_2-$

$-\text{CH}_2\text{OCH}_2-$ and


$-\text{OCH}_2\text{O}-$.

6. (Previously presented) The compound of Claim 1, wherein R_2 is an optionally substituted phenyl or an optionally substituted pyridyl.

7. (Previously presented) The compound of Claim 1, wherein L is




wherein W is oxygen, A is selected from the group consisting of linear or branched C1-5 alkyl and a group of formula (J):




wherein R₃ is methyl or isopropyl.

8. (Previously presented) The compound of claim 1 wherein L is




wherein E is selected from the group consisting of propyl, isobutyl and phenyl substituted by at least one of methyl and/or methoxy.

9. (Previously presented) The compound of any one of Claim 1, wherein L is
















wherein T is oxygen or sulfur, G is ethyl or propyl.

10. (Original) The compound of Claim 1, which is represented by the formula:




wherein R₂ and L are selected from the following combinations:

R ₂	L
	$\text{CH}_2\text{C}(=\text{O})\text{N}(\text{CH}_3)\text{C}_4\text{H}_8$
	$\text{CH}_2\text{C}(=\text{O})\text{N}(\text{CH}_3)\text{C}_4\text{H}_8$
	$\text{CH}_2\text{C}(=\text{O})\text{N}(\text{CH}_3)\text{C}_4\text{H}_8$
	$\text{CH}_2\text{C}(=\text{O})\text{N}(\text{CH}(\text{CH}_3)_2)\text{C}_4\text{H}_8$
	$\text{CH}_2\text{C}(=\text{O})\text{N}(\text{CH}(\text{CH}_3)_2)\text{C}_4\text{H}_8$
	$\text{CH}_2\text{C}(=\text{O})\text{N}(\text{CH}(\text{CH}_3)_2)\text{C}_4\text{H}_8$
	$\text{CH}_2\text{C}(=\text{O})\text{N}(\text{CH}_3)\text{C}_4\text{H}_8$








R ₂	L
	$\text{CH}_2\text{C}(=\text{O})\text{OCH}_2\text{CH}_2\text{CH}_3$
	$\text{CH}_2\text{C}(=\text{O})\text{OCH}_2\text{CH}(\text{CH}_3)_2$
	$\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_3$
	$\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2\text{CH}_3$
	






or a pharmaceutically acceptable salt thereof.

11. (Original) The compound of claim 1, which is represented by the formula:




wherein R₂ and L are selected from the following combinations:

R ₂	L
	$\text{CH}_2\text{C}(=\text{O})\text{N}(\text{CH}_3)\text{C}_4\text{H}_8$
	$\text{CH}_2\text{C}(=\text{O})\text{N}(\text{CH}_3)\text{C}_4\text{H}_8$
	$\text{CH}_2\text{C}(=\text{O})\text{N}(\text{CH}_3)\text{C}_4\text{H}_8$
	$\text{CH}_2\text{C}(=\text{O})\text{N}(\text{CH}(\text{CH}_3)_2)\text{C}_4\text{H}_8$
	$\text{CH}_2\text{C}(=\text{O})\text{N}(\text{CH}(\text{CH}_3)_2)\text{C}_4\text{H}_8$
	$\text{CH}_2\text{C}(=\text{O})\text{N}(\text{CH}(\text{CH}_3)_2)\text{C}_4\text{H}_8$
	$\text{CH}_2\text{C}(=\text{O})\text{N}(\text{CH}_3)\text{C}_4\text{H}_8$


R ₂	L
	$\text{CH}_2\text{C}(=\text{O})\text{OCH}_2\text{CH}_2\text{CH}_3$
	$\text{CH}_2\text{C}(=\text{O})\text{OCH}_2\text{CH}(\text{CH}_3)_2$
	$\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_3$
	$\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2\text{CH}_3$
	$\text{CH}_2\text{C}(=\text{O})\text{N}(\text{C}_4\text{H}_8)\text{N}(\text{C}_6\text{H}_{11})$

or a pharmaceutically acceptable salt thereof.


12. (Original) The compound of Claim 1 wherein represented by the formula




or



wherein R₂ is



wherein R₄ is selected from the group consisting of C1-5 alkyl, optionally substituted phenyl and optionally substituted benzyl, and L is



13. (Previously presented) An anesthetic composition for inducing sedative effect and anesthesia in a mammal, comprising an anesthetic effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.

14. (Original) The composition of Claim 13, which is for intravenous injection.

15. (Previously presented) Use of a compound of Claim 1 for manufacturing a pharmaceutical composition for inducing sedative effect and anesthesia in a mammal.

16. (Previously presented) A method for inducing sedative effect and anesthesia in a mammal, comprising the step of administering an anesthetic effective amount of the compound of Claim 1 to the subject in need of anesthesia.